Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMMP 
Immutep Ltd ADR (IMMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: IMMP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.15% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 248.07M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 2 | Beta 1.41 | 52 Weeks Range 1.32 - 2.71 | Updated Date 09/16/2025 |
52 Weeks Range 1.32 - 2.71 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.28 |
Earnings Date
Report Date 2025-09-02 | When Before Market | Estimate -0.1515 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2035.47% |
Management Effectiveness
Return on Assets (TTM) -22.66% | Return on Equity (TTM) -36.88% |
Valuation
Trailing PE - | Forward PE 7.65 | Enterprise Value 168590652 | Price to Sales(TTM) 49.18 |
Enterprise Value 168590652 | Price to Sales(TTM) 49.18 | ||
Enterprise Value to Revenue 803.42 | Enterprise Value to EBITDA -2.94 | Shares Outstanding 146786000 | Shares Floating 1225123984 |
Shares Outstanding 146786000 | Shares Floating 1225123984 | ||
Percent Insiders 0.01 | Percent Institutions 1.91 |
Upturn AI SWOT
Immutep Ltd ADR
Company Overview
History and Background
Immutep Ltd ADR was founded in 2001 (originally Prima Biomed). It is an Australian biotechnology company focused on cancer immunotherapy. The company's core technology is based on the LAG-3 immune control point.
Core Business Areas
- LAG-3 Immunotherapy: Focuses on developing immunotherapeutic products based on Lymphocyte Activation Gene-3 (LAG-3). This involves monoclonal antibodies and soluble LAG-3 fusion proteins to activate T cells to eliminate cancer cells.
Leadership and Structure
The company is led by CEO Marc Voigt. It has a board of directors and a management team responsible for overseeing the development and commercialization of its products.
Top Products and Market Share
Key Offerings
- Eftilagimod Alpha (Efti): A soluble LAG-3 fusion protein. Used in combination with chemotherapy or other immunotherapies to treat various cancers. Currently in multiple clinical trials. There is no current market share or product revenues. Competitors include BMS (Opdivo) and Merck (Keytruda).
Market Dynamics
Industry Overview
The cancer immunotherapy market is rapidly growing due to its improved success in comparison to other cancer treatments. It is being driven by technological advances, increased funding for cancer research, and an aging population. The overall oncology market is highly competitive, with many companies developing innovative therapies.
Positioning
Immutep Ltd ADR is positioned as a specialist in LAG-3 immunotherapy, differentiating it from companies focused on other immune checkpoints like PD-1/PD-L1 or CTLA-4.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars by 2030. Immutep's addressable market depends on the indications for which Efti is approved. Immutep aims to capture a share of this market through successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel LAG-3 technology platform
- Strong intellectual property portfolio
- Multiple clinical trials underway
- Experienced management team
- Partnerships with major pharmaceutical companies
Weaknesses
- Dependence on clinical trial outcomes
- No currently marketed products
- Limited financial resources compared to larger competitors
- High attrition rate in clinical trials
- Reliance on collaborations
Opportunities
- Expanding indications for Efti
- Partnering with other companies to develop combination therapies
- Potential for breakthrough therapy designation
- Acquisition by a larger pharmaceutical company
- Positive data from ongoing clinical trials
Threats
- Failure of clinical trials
- Competition from other immunotherapy companies
- Changes in regulatory landscape
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- BMS (BMY)
- MRK (MRK)
- AZN (AZN)
Competitive Landscape
Immutep's LAG-3 technology is novel, but it faces competition from companies with approved PD-1/PD-L1 inhibitors (BMY, MRK, AZN) and other immunotherapies. Immutep's competitive advantage lies in the potential for Efti to be used in combination with other therapies.
Growth Trajectory and Initiatives
Historical Growth: Historically, the company's growth has been driven by preclinical and clinical development of its pipeline products and also by share offerings.
Future Projections: Future growth is dependent on positive clinical trial results and successful commercialization of Efti. Analyst estimates vary based on clinical trial outcomes, with future projections dependent on product approvals.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials, securing funding, and developing new product candidates.
Summary
Immutep is a clinical-stage biotechnology company pioneering LAG-3 immunotherapy. Its growth potential hinges on clinical trial outcomes for Efti, a soluble LAG-3 fusion protein. The company faces competition from larger, established players in the immunotherapy market. Success depends on positive clinical data, strategic partnerships, and securing regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immutep Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 2012-04-17 | CEO, MD, CFO, Chief Business Officer & Executive Director Mr. Marc Voigt | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.immutep.com |
Full time employees - | Website https://www.immutep.com | ||
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.